Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report)'s share price shot up 9.3% on Monday . The stock traded as high as $17.29 and last traded at $17.29. 666 shares changed hands during trading, a decline of 96% from the average session volume of 17,672 shares. The stock had previously closed at $15.82.
Analyst Upgrades and Downgrades
TLX has been the subject of several research analyst reports. UBS Group began coverage on Telix Pharmaceuticals Limited American Depositary Shares in a research report on Friday, November 15th. They issued a "buy" rating and a $21.00 price objective for the company. William Blair upgraded shares of Telix Pharmaceuticals Limited American Depositary Shares to a "strong-buy" rating in a report on Tuesday, November 19th.
Read Our Latest Stock Analysis on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Down 2.7 %
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
See Also
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
